ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.72) by $0.17. The firm had revenue of $30.50 million for the quarter, compared to analyst estimates of $20.02 million. ACADIA Pharmaceuticals had a negative net margin of 485.14% and a negative return on equity of 62.08%. The business's revenue for the quarter was up 30400.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.63) EPS. View ACADIA Pharmaceuticals' Earnings History.

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for ACADIA Pharmaceuticals.

13 equities research analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $25.00 to $61.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $47.54 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (10/16/2017)
• 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)
• 3. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

ACADIA Pharmaceuticals saw a decline in short interest in the month of September. As of September 29th, there was short interest totalling 6,510,387 shares, a decline of 60.7% from the September 15th total of 16,574,500 shares. Based on an average trading volume of 1,050,533 shares, the short-interest ratio is presently 6.2 days. Currently, 5.3% of the shares of the company are short sold.

Some companies that are related to ACADIA Pharmaceuticals include Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alkermes PLC (ALKS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), United Therapeutics Corporation (UTHR), Galapagos NV (GLPG), Bio-Techne Corp (TECH), Puma Biotechnology (PBYI), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Ligand Pharmaceuticals Incorporated (LGND), INC Research Holdings (INCR) and Portola Pharmaceuticals (PTLA).

ACADIA Pharmaceuticals' management team includes the folowing people:

• Stephen R. Biggar M.D. Ph.D., Chairman of the Board
• Stephen R. Davis, President, Chief Executive Officer, Director
• Todd S. Young, Executive Vice President, Chief Financial Officer
• Glenn F. Baity, Executive Vice President, General Counsel, Secretary
• Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development
• Michael J. Yang, Executive Vice President, Chief Commercial Officer
• Edmund P. Harrigan M.D., Director
• Julian C. Baker, Independent Director
• Laura A. Brege, Independent Director
• James M. Daly, Independent Director

ACADIA Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (22.10%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $35.83.